The role of abemaciclib in treatment of advanced breast cancer

The role of abemaciclib in treatment of advanced breast cancer

Until recently, the mainstay of treatment in the majority of hormone receptor (HR)-positive, human epidermal growth factor 2 receptor (HER2)-negative advanced breast cancer (ABC) has consisted of single-agent endocrine therapy (ET). However, as understanding of endocrine resistance has grown, newer...

Full description

Bibliographic Details
Main Authors:	Amelia McCartney, Erica Moretti, Giuseppina Sanna, Marta Pestrin, Emanuela Risi, Luca Malorni, Laura Biganzoli, Angelo Di Leo
Format:	Article
Language:	English
Published:	SAGE Publishing 2018-05-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758835918776925

Similar Items

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
by: Lorenzo Rossi, et al.
Published: (2018-12-01)

Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer
by: Alessia Vignoli, et al.
Published: (2021-04-01)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
by: Lorenzo Rossi, et al.
Published: (2019-05-01)

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial
by: Francesca Galardi, et al.
Published: (2021-03-01)

Profile of abemaciclib and its potential in the treatment of breast cancer
by: Martin JM, et al.
Published: (2018-08-01)

Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?
by: Natalie Turner, et al.
Published: (2014-03-01)

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
by: Stephen Johnston, et al.
Published: (2021-06-01)

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib
by: Natansh D. Modi, et al.
Published: (2021-08-01)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
by: Corona SP, et al.
Published: (2018-02-01)

Efficiency and tolerability of abemaciclib in elderly patients
by: E. I. Kovalenko, et al.
Published: (2020-12-01)

Subacute cutaneous lupus erythematosus following abemaciclib therapy for metastatic breast cancer
by: David J. Kurtyka, MS, et al.
Published: (2021-08-01)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
by: Amelia McCartney, et al.
Published: (2019-07-01)

FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
by: Amiri-Kordestani, L., et al.
Published: (2022)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
by: Claudia Omarini, et al.
Published: (2020-08-01)

MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study
by: Qing Yuan Zhang, et al.
Published: (2020-10-01)

Molecular docking and machine learning analysis of Abemaciclib in colon cancer
by: Jose Liñares-Blanco, et al.
Published: (2020-07-01)

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
by: Emanuela Risi, et al.
Published: (2019-12-01)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
by: Ilenia Migliaccio, et al.
Published: (2021-05-01)

Abemaciclib as an original inhibitor of cyclin-dependent kinase for the treatment of luminal HER2-negative disseminated breast cancer
by: N. S. Besova
Published: (2020-07-01)

Radiation recall dermatitis with abemaciclib developing a year after radiotherapy
by: Archya Dasgupta, et al.
Published: (2021-03-01)

EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer
by: Laura Biganzoli, et al.
Published: (2020-08-01)

Significance of Micrometastases: Circulating Tumor Cells and Disseminated Tumor Cells in Early Breast Cancer
by: Catherine Oakman, et al.
Published: (2010-06-01)

Cell-Free DNA-Methylation-Based Methods and Applications in Oncology
by: Francesca Galardi, et al.
Published: (2020-12-01)

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective
by: Yingcheng Wang, et al.
Published: (2021-06-01)

Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics
by: Emmanuel Chigutsa, et al.
Published: (2020-09-01)

Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review
by: Isabella O. Wender, et al.
Published: (2020-09-01)

Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
by: Muh-Lii Liang, et al.
Published: (2020-12-01)

Quantification of abemaciclib and metabolites: Evolution of bioanalytical methods supporting a novel oncolytic agent
by: Lee, L.B, et al.
Published: (2021)

Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature
by: Hong-Fei Gao, et al.
Published: (2021-10-01)

Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report
by: Vittorio Gebbia, et al.
Published: (2021-09-01)

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
by: Patrick Neven, et al.
Published: (2021-08-01)

Analysis of the clinical efficacy of the cyclin- dependent kinase inhibitor 4/6 Abemaciclib on the clinical case of a male with hormonereceptor- positive breast cancer
by: А. Y. Goryainova, et al.
Published: (2021-06-01)

In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach
by: Fleisher B, et al.
Published: (2021-02-01)

Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC–MS/MS: in vitro metabolic investigation
by: Adnan A. Kadi, et al.
Published: (2019-01-01)

Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study
by: Melissa Mahoney, et al.
Published: (2020-12-01)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
by: Silvia La Monica, et al.
Published: (2021-12-01)

PI3K p110α Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells
by: Hyun Jung Lee, et al.
Published: (2020-09-01)

Counsellors' perspectives on how mindfulness meditation influences counsellor presence within the therapeutic relationship.
by: McCartney, Laura Lynn.
Published: (2008)

Unpacking Self in Clutter and Cloth: Curator as Artist/Researcher/Teacher
by: McCartney, Laura Lee
Published: (2016)

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer
by: Catherine Oakman, et al.
Published: (2010-01-01)